MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma

Leukemia

Volumn 26, Issue 2, 2012, Pages 340-348

  Ramakrishnan, V ^a   Ansell, S ^a   Haug, J ^a   Grote, D ^a   Kimlinger, T ^a   Stenson, M ^a   Timm, M ^a   Wellik, L ^a   Halling, T ^a   Rajkumar, S V ^a   Kumar, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

apoptosis; GSI; myeloma; non Hodgkin's lymphoma; notch

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN D1; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MRK 003; MYC PROTEIN; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN P21; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR INTERACTION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CYCLIC S-OXIDES; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIADIAZOLES;

EID: 84856721785     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.192     Document Type: Article

References (48)

1. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009; 16: 633-647.
2. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell 1997; 90: 281-291. (Pubitemid 27329713)
3. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000; 228: 151-165. (Pubitemid 32011983)
4. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000; 5: 207-216. (Pubitemid 30628080)
5. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ et al. A ligand-induced extracellular cleavage regulates gammasecretase-like proteolytic activation of Notch1. Mol Cell 2000; 5: 197-206. (Pubitemid 30628079)
6. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999; 398: 518-522.
7. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 1998; 393: 382-386. (Pubitemid 28269713)
8. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003; 194: 237-255. (Pubitemid 36176887)
9. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A et al. Notch1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 2006; 103: 18261-18266. (Pubitemid 44871646)
10. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001; 20: 3427-3436. (Pubitemid 32634350)
11. Cheng P, Zlobin A, Volgina V, Gottipati S, Osborne B, Simel EJ et al. Notch-1 regulates NF-kappaB activity in hemopoietic progenitor cells. J Immunol 2001; 167: 4458-4467. (Pubitemid 32954323)
12. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 2001; 21: 5925-5934.
13. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, Beverly LJ et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009; 69: 5312-5320.
14. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004; 64: 6854-6857. (Pubitemid 39330990)
15. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I et al. Activation of Notch1 signaling is required for beta-cateninmediated human primary melanoma progression. J Clin Invest 2005; 115: 3166-3176. (Pubitemid 41567581)
16. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66: 649-661. (Pubitemid 121001701)
17. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3: 587-613. (Pubitemid 351488294)
18. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, Tolle G et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006; 108: 1151-1157. (Pubitemid 44232009)
19. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271. (Pubitemid 39336870)
20. Lee SY, Kumano K, Nakazaki K, Sanada M, Matsumoto A, Yamamoto G et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci 2009; 100: 920-926.
21. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004; 103: 3503-3510. (Pubitemid 38525684)
22. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005; 106: 3898-3906.
23. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515. (Pubitemid 38525685)
24. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99: 3398-3403. (Pubitemid 34525322)
25. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008; 111: 2220-2229. (Pubitemid 351451536)
26. Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R et al. Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia 2008; 22: 2273-2277.
27. Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 2009; 69: 3060-3068.
28. Watters JW, Cheng C, Majumder PK, Wang R, Yalavarthi S, Meeske C et al. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 2009; 69: 8949-8957.
29. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009; 136: 1741-1749, e1746.
30. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007; 67: 8051-8057. (Pubitemid 47395139)
31. Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29: 1190-1202.
32. Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T et al. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol 2010; 85: 675-686.
33. Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N et al. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia 2005; 19: 1253-1261. (Pubitemid 40946012)
34. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104: 4188-4193. (Pubitemid 39620173)
35. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104: 1159-1165. (Pubitemid 39038038)
36. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
37. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005; 65: 8690-8697. (Pubitemid 41377356)
38. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444: 1032-1037. (Pubitemid 46018516)
39. Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica 2006; 91: 1033-1040. (Pubitemid 44204768)
40. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-2031. (Pubitemid 37322133)
41. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
42. Li L, Milner LA, Deng Y, Iwata M, Banta A, Graf L et al. The human homolog of rat Jagged1 expressed by marrow stroma inhibits differentiation of 32D cells through interaction with Notch1. Immunity 1998; 8: 43-55. (Pubitemid 28097822)
43. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001; 61: 3200-3205. (Pubitemid 32691976)
44. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ. Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 2007; 110: 278-286. (Pubitemid 47026845)
45. O0Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
46. Oswald F, Liptay S, Adler G, Schmid RM. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 1998; 18: 2077-2088. (Pubitemid 28152657)
47. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003; 22: 2417-2421. (Pubitemid 36560725)
48. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882. (Pubitemid 38445862)